Neutrophil estimation and prognosis analysis based on existing lung squamous cell carcinoma datasets: the development and validation of a prognosis prediction model
This study established a risk-score model that effectively predicts the prognosis of LUSC patients and sheds light on the molecular mechanisms involved. The findings enhance the understanding of neutrophil-tumor interactions, offering potential targets for personalized treatments. However, further experimental validation and clinical studies are required to confirm these findings and address study limitations, including reliance on public databases and focus on a specific lung cancer subtype.
Authors
- Jimmy T. Efird (ORCID: https://orcid.org/0000-0002-4890-5111)
- Alina Basnet (ORCID: https://orcid.org/0000-0002-0062-9007)
- Nobuhiko Seki (ORCID: https://orcid.org/0000-0002-0732-5348)
- Youyu Wang (ORCID: https://orcid.org/0000-0003-3198-7568)
- Dongfang Li (ORCID: https://orcid.org/0009-0001-1157-5737)
- Qiang Li (ORCID: https://orcid.org/0000-0002-3811-5562)
Institutions
- SUNY Upstate Medical University (US)
- Program Support Center (US)
- Southern Medical University Shenzhen Hospital (CN)
- University School (US)
- Case Western Reserve University (US)
- Teikyo University (JP)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2024-08-01
- DOI
- https://doi.org/10.21037/tlcr-24-411
- Citations
- 3
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Taiho Pharmaceutical
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Daiichi Sankyo Europe